Pharmac Improves Access To Breast Cancer Treatments
0
From 1 July, ribociclib (branded as Kisqali) will be funded for a form of advanced breast cancer known as HR-positive HER2-negative locally advanced or metastatic breast cancer. Palbociclib (branded as Ibrance) has been funded for this type of breast ...